[Biomarkers in endocrinology].
d'Herbomez M, Bauters C, Cortet-Rudelli C, Dewailly D, Docao C, Wémeau JL.
Presse Med. 2014 Jan;43(1):40-56. doi: 10.1016/j.lpm.2013.11.003. Epub 2013 Dec 15.
Thyroid nodules: alpha guide to assessment, treatment and follow-up.
Paschou SA, Vryonidou A, Goulis DG.
Maturitas. 2017 Feb;96:1-9. doi: 10.1016/j.maturitas.2016.11.002. Epub 2016 Nov 9.
Gallium-68 Dotatate PET/CT is superior to other imaging modalities in the detection of medullary carcinoma of the thyroid in the presence of high serum calcitonin.
Tran K, Khan S, Taghizadehasl M, Palazzo F, Frilling A, Todd JF, Al-Nahhas A.
Hell J Nucl Med. 2015 Jan-Apr;18(1):19-24. doi: 10.1967/s002449910163. Epub 2015 Feb 13.
Medullary thyroid carcinoma and calcitonin.
Emmertsen K.
Dan Med Bull. 1985 Mar;32(1):1-28.
Calcitonin: physiology or fantasy?
Davey RA, Findlay DM.
J Bone Miner Res. 2013 May;28(5):973-9. doi: 10.1002/jbmr.1869.
Calcitonin, the forgotten hormone: does it deserve to be forgotten?
Felsenfeld AJ, Levine BS.
Clin Kidney J. 2015 Apr;8(2):180-7. doi: 10.1093/ckj/sfv011. Epub 2015 Mar 20.
Long-Term Follow-up in Medullary Thyroid Carcinoma.
Raue F, Frank-Raue K.
Recent Results Cancer Res. 2015;204:207-25. doi: 10.1007/978-3-319-22542-5_10.
[How to interprete hypercalcitoninemia?].
Levy-Bohbot N, Patey M, Larbre H, Hecart AC, Caron J, Delemer B.
Rev Med Interne. 2006 Aug;27(8):610-5. doi: 10.1016/j.revmed.2006.02.010. Epub 2006 Apr 19.
Novel strategies in drug discovery of the calcium-sensing receptor based on biased signaling.
Thomsen AR, Smajilovic S, Bräuner-Osborne H.
Curr Drug Targets. 2012 Sep 1;13(10):1324-35. doi: 10.2174/138945012802429642.
Long-term excess of endogenous calcitonin in patients with medullary thyroid carcinoma does not affect bone mineral density.
Wüster C, Raue F, Meyer C, Bergmann M, Ziegler R.
J Endocrinol. 1992 Jul;134(1):141-7. doi: 10.1677/joe.0.1340141.
